A retrospective records review of patients with periodic fever syndromes (PFS) receiving IL-1 inhibitor treatment with canakinumab (CAN), shows CAN to be effective and safe in a variety of PFS patients. https://t.co/4lqMhE6ikx #RheumNow #RheumTwitter #medtwitter https://t.co/yThiwJhcwO
StillsNow
An educational site for Physicians and Patients with Still's disease (systemic juvenile idiopathic arthritis), periodic fever syndromes and autoinflammatory diseases
